Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...

On Wednesday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.59 which represents a decrease of $-0.07 or -10.61% from the prior close of $0.66. The stock opened at $0.65 and ...

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...

Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to ...

Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had ...

On Monday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.81 which represents a decrease of $-0.01 or -1.22% from the prior close of $0.82. The stock opened at $0.83 and ...

Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.

Fintel reports that on October 24, 2024, JP Morgan downgraded their outlook for Seres Therapeutics (NasdaqGS:MCRB) from Neutral to Underweight. Analyst Price Forecast Suggests 456.13% Upside As of ...

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have earned an average rating of “Hold” from the four brokerages that are presently covering the stock, MarketBeat Ratings ...

Within two days of the election, Newsom positioned himself at the forefront of the opposition, calling for state lawmakers to convene an emergency special session "to safeguard California values" in ...